Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BsUFA III Talks Begin With Regulatory Science Disagreement

May 04 2021

• By Derrick Gingery

Anti-recessionary injection (vaccination) by hundred dollar denomination close up on a black background — Negotiations to extend BsUFA another five years began in March • Source: Shutterstock

Related Content

PDUFA VII Talks Begin With Similar Goals For Industry, US FDA

Oct 04 2020

New Supplement Timelines, Categories Proposed For BsUFA III

May 04 2021

BsUFA III: Reauthorization Process Begins With US FDA Considering Staffing, Uptake Issues

Nov 18 2020

BsUFA III: Sponsors Want Formal Meetings That Don’t Require Product Analytic Data

Nov 20 2020

Predicting The User Fee Reauthorization Schedule

Feb 04 2020

FDA Biosimilars Chief Leah Christl Joining Amgen; Agency Veteran Sarah Yim Takes Her Place

Feb 03 2019

FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

Sep 11 2019

GDUFA III: Some Goals May Be Measured In Business Days Instead Of Calendar Days

Mar 18 2021

PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing

Mar 22 2021

Related Companies

Amgen, Inc.

Gilead Sciences, Inc.

Additional Topics

United States Biosimilars User Fees Regulation FDA BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window